Cullinan Therapeutics, Inc.
Financials
Valuation Metrics
Cullinan Therapeutics, Inc.'s Market Cap is $961M. At end of 2025 it was $613M. Ranked #2429 of 3,118 in US market (top 78%), #992 of 1,474 on NASDAQ (top 67%), #179 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 68%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $961M | US#2,429/3,118 Sec#179/265 |
| Revenue | $0.00 | US#2,858/3,118 Sec#193/265 |
| Net Income | $-205M | US—/3,118 Sec—/265 |
| Total Assets | $364M | US#2,868/3,118 Sec#196/265 |
| Net Assets | $322M | US#2,478/3,118 Sec#152/265 |
| Employees | 109 | US#2,596/3,118 Sec#170/265 |
| Value | ||
| P/B | 2.99x | US#1,783/3,118 Sec#98/265 |
| FCF Yield | -16.58% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROE | -63.62% | US#2,722/3,118 Sec#181/265 |
| ROA | -56.27% | US#3,002/3,118 Sec#226/265 |
| Financial Health | ||
| Debt Ratio | 13.06% | US#147/3,118 Sec#61/265 |
| Total Debt | $2M | US#2,939/3,118 Sec#232/265 |
| FCF | $-159M | US#2,728/3,118 Sec#187/265 |
| Cash | $79M | US#2,355/3,118 Sec#194/265 |
| Current Ratio | 8.42x | US#298/3,118 Sec#89/265 |
| Performance | ||
| 1Y Return | 72.40% | US#149/3,118 Sec#37/265 |
| 1M Return | -3.74% | US#1,965/3,118 Sec#128/265 |
| From 52W High | -35.62% | US#2,159/3,118 Sec#146/265 |
| 1Y MDD | -43.66% | US#2,109/3,118 Sec#139/265 |
| Trading | ||
| Volume | 599,202 shares | US#2,475/3,118 Sec#236/265 |
| Trading Value | $9M | US#2,689/3,118 Sec#219/265 |
| Per Share | ||
| EPS | $-3.18 | US—/3,118 Sec—/265 |
| BPS | $5.00 | US#2,276/3,118 Sec#127/265 |
Company Info
Cullinan Therapeutics, Inc. operates as a biopharmaceutical firm actively advancing its therapeutic candidates through clinical trials. This company is focused on developing innovative treatments primarily for cancer, including those that leverage the immune system (immuno-oncology). Its current roster of investigational drugs comprises CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. Patrick A. Baeuerle founded the organization on September 15, 2016, and it is presently headquartered in Cambridge, Massachusetts.